Evidence map›Paper›PMID 32332068›Full record

ArticleBMJ open diabetes research & care2020

Pei-Shan Hsieh, Hsieh-Hsun Ho, Shih-Hung Hsieh, Yi-Wei Kuo, Hsiu-Ying Tseng, Hui-Fang Kao, Jiu-Yao Wang

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Adjuvant Probiotics ofFrontiers in endocrinology · 2022
    Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The Impact ofMicroorganisms · 2024
    Review
  14. Gut bacteria: an etiological agent in human pathological conditions.Frontiers in cellular and infection microbiology · 2024
    Review
  15. Effects ofFrontiers in pharmacology · 2024
    Article
  16. Article
  17. Screening of Potential ProbioticPolish journal of microbiology · 2023
    Article
  18. Article
  19. Microorganisms · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pei-Shan HsiehResearch and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
Hsieh-Hsun HoResearch and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
Shih-Hung HsiehResearch and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
Yi-Wei KuoResearch and Development Department, Glac Biotech Co., Ltd, Tainan, Taiwan.
Hsiu-Ying TsengDepartment of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.
Hui-Fang KaoDepartment of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan.
Jiu-Yao WangDepartment of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan a122@mail.ncku.edu.tw.ORCID 0000-0003-4540-9822
GenMont Biotech (Taiwan) · TWNational Cheng Kung University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPatients with type 2 diabetes mellitus (T2DM) exhibit strong insulin resistance or abnormal insulin production. Probiotics, which are beneficial live micro-organisms residing naturally in the intestinal tract, play indispensable roles in the regulation of host metabolism. However, the detailed mechanisms remain unclear. Here, we evaluate the mechanisms by which probiotic strains mediate glycemic regulation in the host. The findings should enable the development of a safe and natural treatment for patients with T2DM. RESEARCH DESIGNS AND

methodsSugar consumption by more than 20 strains of

resultsAmong the tested strains,

conclusionOur data elucidate a novel role for probiotics in glycemic regulation in the host.

Indexed as

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Ligilactobacillus salivariusLimosilactobacillus reuteriAnimalsCaco-2 CellsHumansKidneyLiverMicehexokinasemicrobiologynutrient regulationtype 2 diabetes

Identifiers

PMID32332068
PMCPMC7202753
OpenAlexW3018485802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.